Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017 Aldeyra Reports Full Year 2016 Financial Results March 30, 2017 Certara Corporation Releases New Version Of D360, Its Industry-Leading Informatics Platform For Pharma Discovery Scientists January 30, 2017
NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017
Certara Corporation Releases New Version Of D360, Its Industry-Leading Informatics Platform For Pharma Discovery Scientists January 30, 2017